Pharming (PHAR) EBITDA (2020 - 2026)

Pharming (PHAR) has reported EBITDA for 7 consecutive years, with -$3.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA changed N/A year-over-year to -$3.6 million; the trailing twelve-month figure through Jun 2026 stood at $7.3 million (changed N/A YoY), and the FY2025 full-year result was $21.7 million, up 261.75% from the prior year.
• EBITDA advanced to -$3.6 million in Q2 2026 per PHAR's latest filing, from -$4.9 million in the prior quarter.
• Across five years, EBITDA topped out at $28.4 million in Q4 2022 and bottomed at -$19.4 million in Q2 2024.
• Historically, EBITDA has averaged $283176.8 across 5 years, with a median of $1.1 million in 2023.
• The sharpest annual moves came in 2022 and 2024: EBITDA jumped 564.8% in 2022, then sank 1490.91% in 2024.
• Over 5 years, EBITDA stood at $28.4 million in 2022, then tumbled by 96.13% to $1.1 million in 2023, then tumbled by 1490.91% to -$15.3 million in 2024, then surged by 100.0% to $6.2 in 2025, then plunged by 58032358.06% to -$3.6 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$3.6 million, -$4.9 million, and $6.2 for Q2 2026, Q1 2026, and Q4 2025 respectively.